Company / Free Cash Flow per Share
MoonLake Immunotherapeutics Free Cash Flow per Share History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow per Share
-$3.04
FY2025
5-year range
-$4.49 / -$0.88
FY2021-FY2025
Trend
-63.3%
vs FY2024
Sector context
#150 of 192
Health Care
What the data says
MoonLake Immunotherapeutics's free cash flow per share of $-3.04 is lower than 78% of companies in the Health Care sector (FY2025). Declined from $-0.88 to $-3.04 over the past 2 years.
Based on SEC 10-K filings.
-3.04 in FY2025.
Declined from $-0.88 to $-3.04 over the past 2 years.
Health Care sector context is included.
Free Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 22% in Health CareTop 78% of 192This company -$3.04 Sector average -$19.84
▼
+84.7% above sector average
Key checks
Key Insights
- In FY2025, free cash flow per share decreased 63.3% year-over-year.
- Ranks #150 out of 192 companies in the Health Care sector.
- Peak free cash flow per share was recorded in FY2023.
- Lowest free cash flow per share in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.09 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$3.04 | -63.3% |
| FY2024 | -$1.86 | -112.5% |
| FY2023 | -$0.88 | +54.0% |
| FY2022 | -$1.90 | +57.6% |
| FY2021 | -$4.49 | - |
| FY2020 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026